129 related articles for article (PubMed ID: 2613061)
1. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
[No Abstract] [Full Text] [Related]
2. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
Cappellari A; Bagarella M; Corradi G
Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
[TBL] [Abstract][Full Text] [Related]
3. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
[No Abstract] [Full Text] [Related]
5. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor markers in breast cancer.
Tondini C; Hayes DF; Kufe DW
Hematol Oncol Clin North Am; 1989 Dec; 3(4):653-74. PubMed ID: 2691493
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
Zervoudis S; Peitsidis P; Iatrakis G; Panourgias E; Koureas A; Navrozoglou I; Dubois JB
J BUON; 2007; 12(4):487-92. PubMed ID: 18067207
[TBL] [Abstract][Full Text] [Related]
9. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
Jäger W
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
[No Abstract] [Full Text] [Related]
10. [Clinical study of CA15-3 in human breast cancer].
Nihei M; Nomizu T; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1987 Jun; 22(5):987-95. PubMed ID: 3480326
[No Abstract] [Full Text] [Related]
11. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
[No Abstract] [Full Text] [Related]
12. MCA performance in preoperative breast cancer patients.
Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
[TBL] [Abstract][Full Text] [Related]
13. [General and specific laboratory parameters within the scope of tumor after-care in gynecologic malignancies and breast cancer].
Kreienberg R
Gynakologe; 1989 Feb; 22(1):55-62. PubMed ID: 2653979
[No Abstract] [Full Text] [Related]
14. False elevation of serum CA 15-3 levels in patients under follow-up for breast cancer.
Aguiar-Bujanda D; Bohn-Sarmiento U; Aguiar-Morales J
Breast J; 2004; 10(4):375-6. PubMed ID: 15239804
[No Abstract] [Full Text] [Related]
15. A new tumor marker MCA in breast cancer diagnosis.
Eskelinen M; Tikanoja S; Collan Y
Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the BT-1 serum assay for breast cancer.
Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
[TBL] [Abstract][Full Text] [Related]
17. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
Heinze T; Lichtenegger W
Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
[TBL] [Abstract][Full Text] [Related]
18. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
19. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
20. CAM 26 and CAM 29: methodological evaluations and first clinical employment in breast cancer.
Priolo G; Pecchio F; Rapellino M; Aimo G; Spertino F; Pepe C
J Nucl Med Allied Sci; 1990; 34(4 Suppl):21-3. PubMed ID: 2092121
[No Abstract] [Full Text] [Related]
[Next] [New Search]
